Method for improving the benefit to a subject of a therapy or therapeutic agent
The invention relates to a method for improving the benefit of a therapy or a therapeutic agent to a subject. The method comprises administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and subsequently administering said therapy or said therapeutic agent to the subject. The invention also relates to a method for reducing the effect of pathogenic autoantibodies in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject and optionally (b) subsequently subjecting the subject to a treatment which removes endogenous autoantibodies. The invention also relates to a kit for carrying out a method of the invention.
1. A method for improving the benefit to a subject of a therapy or therapeutic agent, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and (b) subsequently administering said therapy or said therapeutic agent to the subject; wherein:
the amount of said agent administered is sufficient to eliminate Fc receptor binding by IgG molecules present in the serum of the subject; and
steps (a) and (b) are separated by a time interval which is sufficient for Fc receptor binding by IgG molecules present in the serum of the subject to be eliminated;
wherein the agent is a protein having IgG cysteine protease activity from Streptococcus pyogenes which is IgG-degrading enzyme of Streptococcus pyogenes (IdeS), which agent comprises of the amino acid sequence of SEQ ID NO: 1, or a variant thereof comprising of an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1, which variant does not comprise deletions and any amino acid substitutions in the variant are conservative substitutions which conserve amino acid charge.
2. The method according to claim 1 , wherein said agent is administered by intravenous infusion and/or the amount of said agent that is administered is between 0.01 mg/kg BW and 2 mg/kg BW, between 0.04 and 2 mg/kg BW, between 0.12 mg/kg BW and 2 mg/kg BW, between 0.24 mg/kg BW and 2 mg/kg BW, or between 1 mg/kg BW and 2 mg/kgBW.
3. The method according to claim 1 wherein:
the time interval comprises a lower and an upper limit, wherein:
the lower limit of the time interval between steps (a) and (b) is selected from: at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, or at least 6 hours; and
the upper limit of the time interval between steps (a) and (b) is independently selected from: at most 21 days, at most 18 days, at most 14 days, at most 13 days, at most 12 days, at most 11 days, at most 10 days, at most 9 days, at most 8 days, at most 7 days, at most 6 days, at most 5 days, at most 4 days, at most 3 days, at most 2 days, at most 24 hours, at most 18 hours, at most 12 hours, at most 10 hours, at most 8 hours, at most 7 hours or at most 6 hours.
4. The method according to claim 1 , wherein the time interval between steps (a) and (b) is of 30 minutes to 1 hour, 30 minutes to 2 hours, 30 minutes to 3 hours, 30 minutes to 4 hours, 30 minutes to 5 hours, 30 minutes to 6 hours, 1 to 2 hours, 1 to 3 hours, 1 to 4 hours, 1 to 5 hours, 1 to 6 hours, 2 to 3 hours, 2 to 4 hours, 2 to 5 hours, 2 to 6 hours, 3 to 4 hours, 3 to 5 hours, 3 to 6 hours, 4 to 5 hours, 4 to 6 hours, or 5 to 6 hours.
5. The method according to claim 1 , wherein said therapeutic agent is an antibody which is administered for the treatment of cancer or another disease, optionally wherein said cancer is breast cancer.
6. The method according to claim 1 , wherein said therapeutic agent is Trastuzumab.
7. The method according to claim 1 , wherein said therapy is an organ transplant.
8. The method according to claim 7 , further comprising induction of T cell and/or B cell suppression in the subject concurrently or immediately prior to transplantation.
9. The method according to claim 8 , wherein said induction suppression comprises administering an effective amount of at least one of Muromonab, Basiliximab, Daclizumab, an antithymocyte anti-thymocyte globulin (ATG) antibody, a lymphocyte immune globulin, anti-thymocyte globulin preparation (ATGAM), or Rituximab.
10. The method of claim 1 , wherein the agent consists of the amino acid sequence of SEQ ID NO: 1, or a variant thereof consisting of an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1, which variant does not comprise deletions and any amino acid substitutions in the variant are conservative substitutions which conserve amino acid charge.
11. The method of claim 7 , wherein the organ is kidney, liver, heart, pancreas, lung, or small intestine.